Previsioni

Il prezzo obiettivo medio degli analisti è +2,58€ (+29,65%). La mediana è +2,58€ (+29,65%).

Acquista	11
Mantieni	1
Vendi	0

Notizie Vai al feed delle notizie

ProQR shares fall despite positive data on AX-0810 and pipeline progress

ProQR shares slipped about 3% even though Phase 1 data from the first cohort for AX-0810 showed no serious adverse events and the pharmacokinetics matched the nonclinical data. Target-engagement data for AX-0810 are expected in the first half of 2026. ProQR also selected AX-2402 (Rett syndrome, MECP2-R270X) and AX-2911 (MASH, PNPLA3) as development candidates after convincing preclinical results, and received $4.5 million in milestone payments from Eli Lilly in 2025, extending its cash runway to mid-2027. » Altro su de.investing.com
ProQR receives EMA approval for phase-1 trial of RNA-editing therapy AX-0810

The CCMO has granted ProQR permission to start a phase-1 trial of the RNA-editing agent AX-0810 in healthy volunteers. The approval was issued under the new centralized EMA review procedure and permits dosing in the Netherlands. The study will assess safety, tolerability, and pharmacokinetics and -dynamics using biomarkers; AX-0810 is the first Axiomer program to enter clinical development. ProQR will hold a virtual investor event on Nov. 3; an analyst most recently confirmed a "Market Outperform" rating with a $8.00 price target. » Altro su de.investing.com
ProQR submits application for clinical trial of RNA editing therapy AX-0810

ProQR has submitted an application to the European Medicines Agency for a Phase 1 clinical trial of its RNA editing therapy AX-0810, which targets cholestatic liver diseases. Initial data are expected in the fourth quarter of 2025, while analysts highlight the company's strong position in RNA editing and its promising pipeline. Additionally, key leadership positions have been filled with Dennis Hom as CFO and Cristina Lopez Lopez as CMO to advance clinical development. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, ProQR Therapeutics ha registrato ricavi pari a 8,90M€ e un utile netto di −8,87M€

(EUR)	giu 2026	YoY
Ricavi	+8,90M	133,27%
Utile lordo	+8,19M	114,44%
Utile netto	−8,87M	27,15%
EBITDA	−8,25M	28,18%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+212,43M€
Numero di azioni	105,31M
Massimo/minimo a 52 settimane	+2,66€ - +1,14€
Dividendi	No
Beta	0,03
Rapporto P/E	−5,09
Rapporto PEG	−0,88
Rapporto P/B	+2,79
Rapporto P/S	+11,43

Profilo aziendale

ProQR Therapeutics N.V., ein biopharmazeutisches Unternehmen, beschäftigt sich mit der Entdeckung und Entwicklung von RNA-basierten Therapeutika für die Behandlung von genetischen Erkrankungen. Es entwickelt in erster Linie Sepofarsen, das sich in der klinischen Phase II/III-Studie Illuminate zur Behandlung der kongenitalen Leber-Amaurose 10 befindet, und Ultevursen, das sich in der klinischen Phase II/III-Studie zur Behandlung der USH2A-vermittelten Retinitis pigmentosa und des Usher-Syndroms befindet. Das Unternehmen befasst sich auch mit der Entwicklung der Axiomer RNA-Base-Editing-Plattformtechnologie. Es hat eine Lizenzvereinbarung mit dem Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc. und dem Leiden University Medical Center sowie eine Lizenz- und Forschungskooperation mit Eli Lilly and Company für die Entdeckung, Entwicklung und Vermarktung potenzieller neuer Medikamente für genetische Störungen der Leber und des Nervensystems. ProQR Therapeutics N.V. wurde im Jahr 2012 gegründet und hat seinen Hauptsitz in Leiden, Niederlande.

Nome	ProQR Therapeutics
CEO	Daniel Anton de Boer
Sede centrale	Leiden, zh Paesi Bassi
Sito web	proqr.com
Settore	Sanità
Industria	Biotecnologia
Quotazione in borsa	18/09/2014
Dipendenti	166